natgillin/translations-raw huggingface dataset:
These effects may be direct or indirect, meaning that they can be caused by either bacterial activities or products, or by products created by digestion in the digestive tract. 
Ti učinci mogu biti izravni ili neizravni, što znači da ih mogu uzrokovati bilo bakterije same, bilo njihovi produkti, ili produkti nastali razgradnjom u probavnom sustavu.
Thiazolidin-4-one derivatives according to claim 18 to 23 wherein R14 represents an unsubstituted, a mono- or disubstituted phenyl group, substituted with methyl or halogen, R15 represents lower alkyl. 
Derivati tiazolidin-4-ona prema zahtjevima 4 do 9, naznačeni time, da R14 predstavlja nesupstituiranu, ili a mono- ili di-supstituiranu fenilnu skupinu, supstituiranu metilom ili halogenom, a R15 predstavlja niži alkil.
Use of an immunostimulatory composition according to any of claims 1 to 16, or an adjuvant component, comprising or consisting of at least one (m)RNA, complexed with a polycationic compound which is a polycationic peptide or protein, and at least one free mRNA, wherein at least one free mRNA encodes at least one antigen, as defined according to any of claims 1 to 12, for preparing a pharmaceutical composition for prophylaxis, treatment, and/or amelioration of any of the diseases and disorders selected from cancers or tumor diseases, autoimmune diseases, infectious diseases, including viral, bacterial or protozoological infectious diseases or allergy or allergic diseases. 
Uporaba imunostimulacijskog pripravka prema bilo kojem zahtjevu od 1 do 16, ili komponenta adjuvanta, koja obuhvaća ili se sastoji od barem jedne (m)RNK, kompleksirane sa polikationskim spojem koji je polikationski peptid ili protein, te barem jedne slobodne mRNK, pri čemu barem jedna slobodna mRNK kodira barem jedan antigen, kako je definirano u bilo kojem zahtjevu od 1 do 12, naznačena time da je za pripravu farmaceutskog pripravka za profilaksu, liječenje i/ili ublažavanje bilo kojih bolesti i poremećaja koji su odabrani od karcinoma ili tumorskih bolesti, autoimunih bolesti, zarazne bolesti, uključujući virusne, bakterijske ili protozoološke zarazne bolesti ili alergije ili alergijske bolesti.
The pharmaceutical composition according to any one of claims 1-2, wherein the sense strand comprises SEQ ID NO:98 and the antisense strand comprises SEQ ID NO:165; wherein the sense strand further comprises 2'-5'-ribonucleotides in positions 15, 16, 17, 18, and 19; a C3-OH 3' moiety covalently attached at the 3'-terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5'-terminus; and wherein the antisense strand further comprises 2'-O-methyl modified ribonucleotides in positions 2, 4, 6, 8, 11, 13, 15, 17, and 19; a 2'-5'-ribonucleotide in position 7; and a C3Pi-C3OH moiety covalently attached at the 3'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što smisleni lanac sadrži SEQ ID NO:98, a protusmisleni lanac sadrži SEQ ID NO:165; gdje smisleni lanac dodatno sadrži 2'-5'- ribonukleotide na položajima 15, 16, 17, 18, te 19; C3-OH 3' ostatak kovalentno vezan na 3'-kraju; i invertirani nebazni deoksiribonukleotidni ostatak kovalentno vezan na 5'-kraju; i gdje protusmisleni lanac dodatno sadrži 2'- O-metilom modificirane ribonukleotide na položajima 2, 4, 6, 8, 11, 13, 15, 17, te 19; 2'-5'-ribonukleotid na položaju 7; i C3Pi-C30H ostatak kovalentno vezan na 3'-kraju.
the a.i. is enriched in the solvent (extraction) and 
(c) djelatni sastojak se obogaćuje u otapalu (ekstrakcija), i
Table 3 shows the effect of compounds on U937 adhesion to activated-HMEC-1. 
Tablica 3 prikazuje učinak spojeva na U937 adheziju na aktivirane HMEC-1.
A compound having the formula I: 
PATENTNI ZAHTJEVI Spoj s formulom I:
the housing comprises a round tube; 
kućište (54) sadržava okruglu cijev;
The compound or salt for use according to claim 23, wherein said cancer is leukemia. 
Farmaceutski sastav za upotrebu prema zahtjevu 28, pri čemu je navedeni rak leukemija.
A method according to any of numbered embodiments 1 to 5, wherein the first rotor has a diameter of 120 to 250mm, and the final rotor has a greater diameter of 180 to 330mm. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 5, pri čemu prvi rotor ima promjer od 120 do 250 mm, i zadnji rotor ima veći promjer od 180 do 330 mm.
is hydrogen, C1-C4 alkyl, which is optionally substituted with one or more R8 groups, or RE which is optionally substituted with one or more R9 groups; 
R* je vodik, C,-Ca alkil, koji je izborno supstituiran s jednom ili više skupina RÅ, ili R*, koji je izborno supstituiran s jednom ili više skupina R';
It is believed that the application of ultrasound will provide the advantage that the curing process which results in a net volume reduction of the bulk will be countered by the volume expansion caused by the martensitic transformation of the filler ingredient. 
Vjeruje se da će primjena ultrazvuka biti pogodna za proces očvršćivanja što dovodi do toga da se smanjivanje volumena samog materijala poništi ekspanzijom volumena uzrokovane martenzitskom transformacijom sastojka za punjenje.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound fenpropidin. 
UA naznačen time da je R, difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj biksafen.
The composition of any one of claims 1-5, wherein the oligosaccharide chain comprises at least one branch having the structure NeuNAc2a3GalB4GlcNAcB2Mana6. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da oligosaharidni lanac sadržava najmanje jednu granu koja ima strukturu NeuNAc2a3GalB4GlcNAcB2Mana6.
A compound according to claim 21 wherein the bacterial infection is an infection with Mycobacterium tuberculosis. 
Spoj prema zahtjevu 21 naznačen time da bakterijska infekcija je infekcija sa bakterijom Mycobacterium tuberculosis.
a polypeptide comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:2, 4, or 6, wherein said polypeptide has glyphosate-tolerance activity; 
polipeptid koji sadrži aminokiselinski odsječak koji ima najmanje 80% identitet odsječka aminokiselinskom odsječku SEQ ID NO: 2, 4 ili 6, pri čemu rečeni polipeptid ima aktivnost tolerancije na glifosat;
Process according to any of the previous claims, wherein said membrane is in a configuration of (parallel) flat plates, or as tubes, capillaries, spiral wound tubes, in which one fluid passes on the lumen side and the other passes on the outside. 
Postupak prema zahtjevu 1, naznačen time, da je spomenuta membrana konstruirana kao paralelno postavljene ravne ploče, ili kao cijevi, kapilarne cijevi, spiralno usječene cijevi, u kojima prolazi jedna tekućina na lumenoj strani, a druga prolazi s vanjske strane lumena.
The word "substantially" does not exclude "completely" e.g. a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention. 
Riječi "u biti" ne isključuje "potpuno", na pr. sastav koji je "u biti" bez Y može biti potpuno bez Y. Gdje je to potrebno, riječi "u biti" se mogu izostaviti iz definicije izuma.
In certain embodiments, the kits comprise a PNP inhibitor and an alkylating agent. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 15, naznačen time što dodatno sadrži alkilirajuće sredstvo.
The injector of any one of claims 1 to 17, wherein the actuator is adapted to delay movement of the container needle from the storage state to the delivery state after an input is received. 
Ubrizgač prema bilo kojem od prethodnih zahtjeva, naznačen time, što je pokretač (456) prilagođen da odgodi kretanje igle spremnika (550, 702, 772) 1z pasivnog stanja u stanje za isporuku nakon primanja unosa.
A method of treating a viral infection, wherein said virus is selected from herpes simplex complex 1 (HSV-1), genital herpes (HSV-2), varicella zoster virus (VZV), Epstein-Barr virus, human herpes virus 8, avian influenza, mumps, HIV, respiratory syncitial virus, influenza virus, parainfluenza virus and cytomegalovirus, comprising: administering to a patient in need thereof a therapeutically effective amount of the mucosal bioadhesive slow release carrier formulation of claim 1 . 
HR P20100039 T1 19. Primjena nosača bioadhezivnog za mukozu sa sporim oslobađanjem prema patentnom zahtjevu 19, naznačen time što se za proizvodnju lijeka za liječenje herpes simpleks kompleksa 1 (HSV-1), genitalnog herpesa (HSV-2), infekcije varičela zoster virusom (VZV), Epstein-Barr virusom, humanim herpes virusom 8, ptičje gripe, zaušnjaka, HIV-a, infekcije respiratornim sincicijalnim virusom, gripe, parainfluence i infekcije citomegalovirusom.
Also, in case of problems with the apparatus there is a need to be able to quickly identify the problem. 
Također, u slučaju problema s aparatom postoji potreba za mogućnošću brze identifikacije problema.
An antibody of any one of claims 8 or 9, wherein said substitutions are I332E, S239D and G236A. An antibody that binds to human CD37 and has a heavy chain comprising the amino acid sequence of SEQ ID NO:28. 
Protutijelo, naznačeno time, da se veže na ljudski CD37 i ima jaki lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:28 i slabi lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:30.
A product according to paragraph 13 wherein 25 to 50%, for example 30 to 50%, of the total sialylation is a2, 6- sialyation. A product according to paragraph 13 or paragraph 14 wherein 50 to 70% of the total sialylation is a 2,3- sialyation. 
Proizvod prema patentnom zahtjevu 7, naznačen time da 1% do 50% ukupne sijalizacije je 02, 6- sijalizacija, a 50% do 99% ukupne sijalizacije je &2.3- sijalizacija.
Specific embodiments include compounds having the structure shown above, where Z is CO2Q, Q is hydrogen, and m is 4. 
Tvar u skladu s patentnim zahtjevom 5, pri čemu je Z jednak CO2Q, Q je vodik, a mje 4.
Tritoqualine for use according to claim 3, wherein the cystic fibrosis complications are selected from infection, inflammatory disorder, more specifically in the respiratory tract, pancreas, gastrointestinal tract, sweat glands, or other exocrine tissues, severe chronic lung disease, pancreatic insufficiency, nasal polyposis, pansinusitis, chronic diarrhea, pancreatitis, cirrhosis or other forms of hepatic dysfunction, sinus disease, diabetes, or hepatobiliary problems, more specifically focal biliary cirrhosis, biliary obstruction and progressive periportal fibrosis. 
Tritokvalin za uporabu prema bilo kojem od zahtjeva 1-3, gdje se komplikacije cistične fibroze izabiru između teške kronične bolesti pluća, insuficijencije gušterače, nazalne polipoze, pansinusitisa, kronične dijareje, pankreatitisa, ciroze ili drugih oblika disfunkcije jetre, bolesti sinusa, dijabetesa ili hepatobilijarnih problema, specifičnije fokalne bilijarne ciroze, bilijarne opstrukcije i progresivne periportalne fibroze.
The individually pocketed coil spring according to any one of the preceding claims, wherein it further comprises a second cushioning pad located below said lower end of said coil spring, said second cushioning pad being arranged in a third compartment, said third compartment being separated from said first and second compartments. 
Pojedinačno ušivena spiralna opruga (2) iz bilo kojeg od prethodnih Zahtjeva, pri čemu nadalje sadrži drugi amortizirajući podložak smješten ispod navedenog donjeg kraja (42) navedene spiralne opruge (4), navedeni drugi amortizirajući podložak smješten je u treći odjeljak, navedeni treći odjeljak odvojen je od navedenih prvog i drugog odjeljka (21, 22).
A patch according to Claim 9, in which the polar monomer is acrylic acid, N-vinyl-2-pyrrolidone or 2-hydroxyethyl acrylate. 
Flaster u skladu s patentnim zahtjevom 9, naznačen time što polarni monomer je akrilna kiselina, N-vinil-2-pirolidon ili 2-hidroksietil-akrilat.
Number of subcultures 
Broj međunarodne objave:
The compound according to claim 1, which is 7-(2-phenyl-3-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid of formula, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, naznačen time, da je to 7-(2-fenil-3-p-tolil-7,8-dihidropirido[2,3-b]pirazin-5(6H)-il)-heptanonska kiselina sljedeće formule: ili njegova farmaceutski prihvatljiva sol.
the term "aryl" indicated phenyl, optionally substituted with one or more halogen, alkyl, alkoxy groups as defined heirein before, cyano or amino groups, which can be the same or different from one another; 
"aril" jest fenil, koji može biti supstituiran s jednim ili više od sljedecih: halogen, alkilna te alkoksilne skupina kako su ovdje prije definirane, cijano ili amino skupina, koje mogu biti iste ili različite; te
closing the switching element and connecting the auxiliary branch with the main branch through the switching element; 
u koraku h) prekidački element (11) je zatvoren, a pomoćna grana (9) povezana je s glavnom granom (8) preko prekidačkog elementa (11);
The pH of the CCM containing the r-hIL-18BP was adjusted to pH 6.1 prior to application into the MEP HYPERCEL® column. 
Prije nanošenja na kolonu MEP HyperCel pH CCM-a koji je sadržavao r-hIL-18BP podešen je na 6.1.
laminating the product obtained in step c. onto a support layer; and 
laminiranje produkta dobivenog u koraku c na nosivi sloj te
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) fluopiram.
The use according to claim 1, wherein the beta blocker is selected from the group consisting of carteolol, oxprenolol, penbutolol, pindolol. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da je beta blokator odabran iz skupine koja se sastoji od karteolola, oksprenolola, penbutolola, pindolola.
In another aspect, the invention provides a kit comprising a compound capable of inhibiting HDAC activity selected from one or more compounds of formula I or a pharmaceutically acceptable salt, or ester thereof, wherein, Z is N or CR*, wherein R* is an optionally substituted alkyl, an optionally substituted acyl, an optionally substituted aryl or an optionally substituted heteroaryl; 
0: ili njegova farmaceutski prihvatljiva sol ili ester, u kojem, Zje N ili CR*, gdje R* je izborno supstituirani alkil, izborno supstituirani acil, izborno supstituirani aril ili izborno supstituirani heteroaril; prsten A je izborno supstituirani aril ili izborno supstituirani heteroaril; prsten B je izborno supstituirani aril ili izborno supstituirani heteroaril;
Some of these fibres have prebiotic properties and are called prebiotic fibres or prebiotic oligo- or polysaccharides. 
Neka od tih vlakana posjeduju prebiotička svojstva te se nazivaju prebiotičkim vlaknima ili_prebiotičkim oligosaharidima ili polisaharidima.
Another embodiment of the present invention relates to a method of improving lower extremity muscle strength comprising administering to a patient with multiple sclerosis an effective amount of a sustained-release aminopyridine composition twice daily, wherein said effective amount is less than about 15 milligrams of aminopyridine. 
Sastav prema bilo kojem od zahtjeva 1 do 3, naznačen time da je postupak tretiranja multiple skleroze odabran od povećanja brzine hoda, poboljšanja mišićne snage donjih ekstremiteta ili poboljšanja mišićnog tonusa donjih ekstremiteta kod pacijenta s multiplom sklerozom.
a data stream stored in the non-transitory computer-readable medium, the data stream comprising an encoded significance map indicating positions of significant transform coefficients within a transform coefficient block, and encoded values of the significant transform coefficients within the transform coefficient block, wherein the encoded significance map comprises first-type syntax elements sequentially encoded into the data stream by context-adaptive entropy encoding, the first-type syntax elements indicating, for associated positions within the transform coefficient block as to whether at the respective position a significant transform coefficient is situated, 
Predviđajući dekoder, naznačen time, da obuhvaća dekoder na bazi transformacije (150, 152) koji je konfiguriran za dekodiranje bloka koeficijenata transformacije uporabom uređaja za dekodiranje signifikacijske mape iz protoka podataka, koja prikazuje pozicije signifikantnih koeficijenata transformacije unutar bloka koeficijenata transformacije, prema bilo kojem od zahtjeva 1 do 9, te za izvođenje transformacije iz spektralne domene u prostornu domenu u bloku koeficijenata transformacije za dobivanje rezidualnog bloka;
The method according to claim 2, wherein the disease is myeloid metaplasia with myelofibrosis (MMM). 
Spoj ili sol za upotrebu prema patentnom zahtjevu 16, naznačen time da je navedeni mijeloproliferativni poremećaj mijeloidna metaplazija sa mijelofibrozom (MMM).
A compound of the formula wherein X is selected from the group consisting of H, F, Cl, Br, and I; 
Spoj formule [image] (SEQ ID br. 2) naznačen time, da se X odabire iz skupine koja se sastoji od H, F, Cl, Br i I;
A method for transmitting broadcasting data in a receiver, the method comprising: receiving a broadcast signal comprising a signal frame, wherein the signal frame comprises preamble symbols including L1 signaling data and an L1 header and data symbols including PLP data, wherein the preamble symbols are divided into L1 blocks and each L1 block has 3408 subcarriers, and wherein the L1 header includes L1 TI mode information that indicates a time interleaving depth and L1_INFO_SIZE information that indicates the half size of the L1 signaling data and L1 block padding data; 
Metoda za obradu emitiranog podatka u prijamniku, metoda obuhvaća: prihvaćanje emitiranog signala koji obuhvaća okvir signala, pri čemu okvir signala obuhvaća simbole početnog niza uključujući konstelacijske vrijednosti koje odgovaraju signalnom podatku razine 1, naznačenom kao signalni podatak L1, 1 zaglavlje razine 1, pri čemu su simboli početnog niza razine 1 podijeljeni u blokove i svaki blok razine 1 ima 3408 podnosača, i pri čemu zaglavlje razine1l uključuje informaciju vrste umetanja vremena razine 1,
An antibody according to any one of claims 1-4 or a pharmaceutical composition according to any one of claims 8-11, for use in the treatment or prophylaxis of a pathological disorder that is mediated by sclerostin or that is associated with an increased level of sclerostin, wherein the pathological disorder is at least one of primary and secondary osteoporosis, osteopenia, osteomalacia, osteogenesis imperfecta, avascular necrosis also known as osteonecrosis, fractures and implant healing including dental implants and hip implants, bone loss due to other disorders such as bone loss associated with HIV infection, cancers, or arthritis. 
Protutijelo prema bilo kojem od zahtjeva 1 do 4, ili farmaceutski sastav prema bilo kojem od zahtjeva 8 do 11, naznačen(0) time, da se upotrebljava za liječenje ili profilaksu patološkog poremećaja koji je posredovan sklerostinom ili je povezan s povećanjem razine sklerostina, pri čemu je patološki poremećaj barem jedan od sljedećih: primarna i sekundarna osteoporoza, osteopenija, osteomalacija, osteogenesis imperfecta, vaskularna nekroza također poznata pod nazivom osteonekroza, frakture i zacjeljivanje implantatima uključujući dentalne implantate i implantate za kuk, gubitak kostiju zbog ostalih poremećaja kao što je gubitak kostiju povezan s HIV - infekcijom, rakom ili artritisom.
A demountable pole dancing stage as claimed in claim 1, wherein at least one of the support members is provided with a radially extendable secondary support member, which can extend radially beyond the support member for bearing on the ground. 
Sklopiva pozornica za ples na šipki iz bilo kojeg prethodnog zahtjeva, pri čemu bar jedan od nosivih elemenata ima vodoravno produljivi sekundarni nosivi element koji se može izvući iz primarnog nosivog elementa i položiti na tlo (podlogu).
A human antibody or antigen-binding fragment of claim 1 or 2, wherein said antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein the HCVR and LCVR comprise amino acid sequences set forth in SEQ ID NO:108 and 110 respectively. 
Humano antitijelo ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, da navedeno antitijelo ili njegov fragment koji veže antigen, sadrži varijabilno područje teškog lanca (HCVR) i varijabilno područje lakog lanca (LCVR), pri čemu HCVR i LCVR sadrže aminokiselinske odsječke navedene redom u SEQ ID NO: 108 i 110.
Alternatively, it could be manually operated or perhaps even by automatic adjustment via sensors. 
Alternativno, njime se može upravljati ručno a možda čak i automatskim podešavanjem preko senzora.
The complex according to claim 3, where Q is —(CH2)n—, n is an integer from 4 to 8, preferably 6, Y is —CH2—COOH and the radioisotope is Y-90. 
Kompleks prema patentnim zahtjevima 3 ili 4, naznačen time što je Q jednako Â«(CH>),-, n je cijeli broj od 4 do 8, poželjno 6, Y je -CH,-COOH i radioaktivni izotop je Y-90.
In Formula (II), R represents a group represented by CR1R2R3, an unsubstituted or substituted C6-10 aryl group, or a cyano group; 
(ID naznačen time što, u Formuli (II), R predstavlja skupinu koja je predstavljena s CR'R*R*, nesupstituiranu ili supstituiranu skupinu C4_19 aril, ili cijano skupinu;
The rather compact size of the system allows it to be placed advantageously relative to the crop to be sprayed, including internally of vehicles. 
Kompaktna veličina sustava omogućuje da se on postavi pogodno u odnosu na usjev kojeg je potrebno prskati, uključujući i unutrašnjost vozila.
A compound of general formula (2) wherein R1, R2 and R3 are defined as in claim 1. 
Formulacija za inhaliranje bez propelanta koja sadrži spoj opće formule (II) kako je definiran u patentnom zahtjevu 1.
A pharmaceutical composition comprising: (i) the compound of any one of claims 1-19 or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable carrier or excipient. 
Farmaceutski pripravak koji sadrži: (i) spoj iz bilo kojeg od zahtjeva 1-19 ili neku njihovu farmaceutski prihvatljivu sol; 1 (11) neki farmaceutski prihvatljiv nosač ili ekscipijent.
An oligomeric lactic acid according to claim 6 containing -10%w/w of HL3 -10%w/w of HL4 
Farmaceutski pripravak prema patentnom zahtjevu 23, pri čemu oligomerna mliječna kiselina sadrži: 7.5% w/w trimera mliječne kiseline;
After dissolution in acetonitrile/water and lyophilization, then trituration with methanol/ether and drying under vacuum, L -Y-glutamyl-3-[(phenylmethyl)sulfonyl]- L -alanyl- D -phenylglycine, 1A, was obtained as a solid product, with 96% purity by LC (ELSD detection). 
Nakon otapanja u acetonitrilfvoda 1 lipofilizacije, trituriran je sa metanol/eter i sušen u vakuumu, dobiveni kruti produkt L-y-glutamil-3-[(fenilmetil)sulfonil]-1-analil-D-fenil glicin, 1A, 96%-tne čistoće pročišćen je pomoću LC (ELSD detekcija).
subsequently providing a further part of the amount of roast and ground coffee starting material on top of the compacted first part in the inner space of the capsule; 
naknadno dobavljanje sljedećeg dijela količine izlaznog materijala pržene i mljevene kave povrh zbijenog prvog dijela u unutrašnjosti kapsule;
said administration of compound of Formula I is preceded by said naloxone administration, optionally wherein said naloxone administration reduces symptoms of overdose or toxicity prior to administration of compounds of Formula I; or 
Spoj za uporabu sukladno patentnom zahtjevu 13, pri čemu navedena primjena naloksona smanjuje simptome predoziranja ili toksičnosti prije primjene spoja.